Cruiserath, Ireland

Cruiserath, Ireland

Facts and Figures

  • Bristol-Myers Squibb manufacturing operations have been located in Ireland since 1964. The company has a Distribution Centre in Shannon, Co. Clare and also has its External Manufacturing and Pharmaceutical Commercial divisions based in Ireland.
  • Bristol-Myers Squibb announced its strategic decision in 2014 to build a new Biologics Manufacturing facility in Cruiserath, Dublin 15. The $1 billion investment solidifies Bristol-Myers Squibb’s relationship and belief in Ireland.
  • In Bristol-Myers Squibb Cruiserath, Dublin 15, a $1 billion biologics manufacturing facility is under construction for the production of our immuno-oncology medicines. We are building the best facility of its kind in the industry, state-of-the-art in its design, technology and processes, but it’s people who will make it work.
  • When fully operational in late 2018, our new Cruiserath biologics plant will employ approximately 440 scientists, engineers, bioprocess operators, quality specialists and other skilled workers, the vast majority of whom will be new hires.
  • The global Headquarters for Bristol-Myers Squibb’s External Manufacturing organization is located in Ireland.
  • Our employees in Blanchardstown, County Dublin and Shannon, County Clare are responsible for managing approximately 100 Contract Manufacturing Sites to ensure our active pharmaceutical ingredients and finished medicines meet the highest standards for reliable supply to patients.
  • Our cross-functional team has expertise in the areas of Supplier relationship management, Supply Chain, Procurement, Quality Operations, Manufacturing Technology and Finance.

Community and Social Progress

  • Bristol Myers-Squibb Cruiserath places great emphasis on supporting worthwhile charities and is committed to maintaining excellent relationships with the local community.
  • Employees at Cruiserath are very active in working with local voluntary organisations, and also hosting fund raising events. These have included sponsored “beard shaves,” quizzes and a cake sale which have raised over €20,000 for cancer research and an Irish Children’s hospital.
  • The Cruiserath facility also supports efforts to protect endangered species. With the assistance of Bristol-Myers Squibb, the Irish Peatland Conservation Council commenced a number of habitat management projects aimed at supporting the population of the endangered Marsh Fritillary butterfly at Lullymore bog in Co. Kildare. The Marsh Fritillary larva nest and feed in the leaves of the bogland plant “Devil's-bit Scabious.” Birch-willow scrub plants encroach upon the semi-natural grassland where the Devil's-bit Scabious thrives in abundance. Left unmanaged, the scrub plants would engulf the rare bog grassland, and would eventually lead to the displacement of the Devil's-bit Scabious and the extinction of the butterfly in the habitat. Two plots were cleared to allow recolonisation of the Devil's-bit Scabious. The plots will be closely managed and monitored by a team including Bristol-Myers Squibb volunteers over a five-year period to evaluate the recolonisation rates of the Devil's-bit Scabious and the butterfly itself.
  • Throughout 2017, we continue to pursue our community-based activities across the globe and across therapeutic areas to help underserved populations and to benefit the places in which we live and work.


  • In 2010 and 2012, one of the Cruiserath Safety Representatives won the National Irish Safety Representative of the Year Award from the National Irish Safety Organisation.
  • The PharmaChemical Ireland Responsible Care Award was received in October 2011 for improvements to the Lockout/Tagout program implemented by the Operational Excellence Team during 2010.
  • Bristol-Myers Squibb Cruiserath is proud of our record of safe operations without adverse environmental impact.
  • The Cruiserath plant is subject to inspection by the Health and Safety Authority (HSA) which enforces safety regulations in Ireland.
  • The Safety Management System at the Cruiserath site has been certified to OSHAS 18001 since 2007.
  • Since 2007, this site has received annual awards from the National Irish Safety Organisation (NISO) for excellence in the management of safety.

Environmental Performance

  • The site is licensed and audited by the Environmental Protection Agency and is required to operate within rigorous management and operational controls as well as specified emission limits.
  • Containment, abatement and waste treatment systems installed at the facility are state-of-the-art and conform to the highest environmental and safety standards.
  • There were no exceedances of any license limit for monitoring parameters in 2011.
  • The total quantity of all waste produced on-site has been reduced by 11.2% in 2011 vs. 2010.
  • Significant decreases were noted in final wastewater annual mass emissions of several parameters in 2011 versus 2010, in BOD, COD, suspended solids and orthophosphate, and decreases noted in metals, fluoride, nitrate, sulphate and chloride.
  • Green House Gas emissions from the main site boilers decreased by 727 Tonnes in 2011 versus 2010.
  • The EHS Laboratory Quality Management System is certified to ISO 17025 for six wastewater test methods.

Energy Efficiency

  • Preservation of our natural resources is one of Bristol-Myers Squibb’s key commitments. The Cruiserath facility is operating to the new European Energy Management Standard EN 16001, which entails a systematic approach to sustainable energy efficiency.
  • The site is committed to energy and carbon emissions reduction. The site has a dedicated energy team lead by a full time energy manager. The reduction of energy is a core objective for the site and receives the full support of senior management.
  • In 2011, a number of energy projects implemented helped sustain improvements and off-set the increases from fewer shutdowns.
  • Ongoing communication on energy issues is achieved by following the planned energy awareness programme for the year. This includes Energy and Environmental Awareness Day, which took place in October 2011. The agenda included site wide posters, power point presentation in the canteen on a variety of energy topics, site wide email communications, quizzes and an employee energy awareness / climate change questionnaire.
  • Over the last 6 years, Bristol-Myers Squibb Ireland’s Carbon footprint has been reduced by over 12,900 metric tons and we continue to pursue innovative ways to further reduce our energy use.

Facility Contact Information

Main site phone number